{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:15:06Z","timestamp":1785204906019,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Beh\u00e7et\u2019s disease (BD) is an autoinflammatory disease that can affect multiple organs, including the gastrointestinal tract. Conventional management comprises anti-inflammatory drugs such as glucocorticoids (GCs) and\/or immunomodulators that alleviate symptoms. The introduction of biological agents that target tumor necrosis factor\u00a0\u03b1 (TNF-\u03b1) has improved disease management. The goal of this work was to analyze the current prevalence and incidence of total BD and gastrointestinal Beh\u00e7et\u2019s disease (GIBD) in Japan, and examine treatment trends, especially regarding the use of TNF-\u03b1 inhibitors (TNF\u03b1i).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective descriptive observational study in which BD and GIBD demographic trends, medical treatment patterns, and reported adverse events (AEs) were assessed among patients with data recorded between 2017 and 2021 in the Japan Medical Data Center Claims Database (now JMDC Inc.).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Prevalence of BD and GIBD in Japan during the observation period increased at an annual rate of\u2009+\u20093% and\u2009+\u20094%, respectively, while incidence decreased by\u2009\u2212\u20095% and\u2009\u2212\u20092%, with a more prominent decline in confirmed GIBD cases (\u2212\u200915%). Although GCs were the most common initial treatment administered, use of TNF\u03b1i for BD and GIBD management increased by\u2009+\u20095.6% and\u2009+\u20098.1%, respectively. Severe AEs (mainly pneumonia and GI-associated AEs) were reported in 40% of patients receiving TNF\u03b1i; however, a high retention rate (of up to 80%) was observed 3\u00a0years after treatment initiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The use of TNF\u03b1i for GIBD treatment has increased in Japan in recent years. Additional research is necessary to further evaluate TNF\u03b1i effectiveness in GIBD and other BD subtypes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-024-02191-y","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:36:34Z","timestamp":1733517394000},"page":"294-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beh\u00e7et\u2019s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan"],"prefix":"10.1007","volume":"60","author":[{"given":"Tadakazu","family":"Hisamatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-7046","authenticated-orcid":false,"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2191_CR1","unstructured":"Adil A, Goyal A, Quint JM. Behcet disease. In: StatPearls. Treasure Island: StatPearls Publishing LLC; 2023."},{"key":"2191_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000520696","volume":"6","author":"A Nguyen","year":"2021","unstructured":"Nguyen A, Upadhyay S, Javaid MA, et al. Behcet\u2019s disease: an in-depth review about pathogenesis, gastrointestinal manifestations, and management. Inflamm Intest Dis. 2021;6:175\u201385.","journal-title":"Inflamm Intest Dis"},{"key":"2191_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s13317-016-0074-1","volume":"7","author":"MJ Zeidan","year":"2016","unstructured":"Zeidan MJ, Saadoun D, Garrido M, et al. Beh\u00e7et\u2019s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7:4.","journal-title":"Auto Immun Highlights"},{"key":"2191_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M de Menthon","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51\/B5 and the risk of Beh\u00e7et\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287\u201396.","journal-title":"Arthritis Rheum"},{"key":"2191_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, Lavalley MP, Cheminant M, et al. Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51:887\u2013900.","journal-title":"Rheumatology (Oxford)"},{"key":"2191_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1080\/14397595.2019.1649103","volume":"30","author":"Y Mizuki","year":"2020","unstructured":"Mizuki Y, Horita N, Horie Y, et al. The influence of HLA-B51 on clinical manifestations among Japanese patients with Beh\u00e7et\u2019s disease: a nationwide survey. Mod Rheumatol. 2020;30:708\u201314.","journal-title":"Mod Rheumatol"},{"key":"2191_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-020-02406-6","volume":"23","author":"Y Soejima","year":"2021","unstructured":"Soejima Y, Kirino Y, Takeno M, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Beh\u00e7et\u2019s disease in Japan. Arthritis Res Ther. 2021;23:49.","journal-title":"Arthritis Res Ther"},{"key":"2191_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/BOR.0000000000000846","volume":"34","author":"M Takeno","year":"2022","unstructured":"Takeno M. The association of Beh\u00e7et\u2019s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34:4\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"2191_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/08830185.2020.1851372","volume":"41","author":"M Mahmoudi","year":"2022","unstructured":"Mahmoudi M, Aslani S, Meguro A, et al. A comprehensive overview on the genetics of Beh\u00e7et\u2019s disease. Int Rev Immunol. 2022;41:84\u2013106.","journal-title":"Int Rev Immunol"},{"key":"2191_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318.","journal-title":"Ann Rheum Dis"},{"key":"2191_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.624795","volume":"8","author":"E Alpsoy","year":"2021","unstructured":"Alpsoy E, Leccese P, Emmi G, et al. Treatment of Beh\u00e7et\u2019s disease: an algorithmic multidisciplinary approach. Front Med (Lausanne). 2021;8: 624795.","journal-title":"Front Med (Lausanne)"},{"key":"2191_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JEP.S265645","volume":"13","author":"BC Bozca","year":"2021","unstructured":"Bozca BC, Alpsoy E. Experimental therapeutic solutions for Behcet\u2019s disease. J Exp Pharmacol. 2021;13:127\u201345.","journal-title":"J Exp Pharmacol"},{"key":"2191_CR13","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","volume":"52","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Beh\u00e7et\u2019s disease refractory to conventional medication. Intern Med. 2013;52:1855\u201362.","journal-title":"Intern Med"},{"key":"2191_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-24131-5_9","volume-title":"Beh\u00e7et syndrome","author":"JH Cheon","year":"2020","unstructured":"Cheon JH, Hatemi I, \u00c7elik AF, et al. Beh\u00e7et syndrome: gastrointestinal involvement. In: Yazici Y, Hatemi G, Seyahi E, et al., editors. Beh\u00e7et syndrome. Cham: Springer International Publishing; 2020, pp. 117\u201341."},{"key":"2191_CR15","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3748\/wjg.v21.i13.3801","volume":"21","author":"W Skef","year":"2015","unstructured":"Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Beh\u00e7et\u2019s disease: a review. World J Gastroenterol. 2015;21:3801\u201312.","journal-title":"World J Gastroenterol"},{"key":"2191_CR16","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmda.go.jp\/english\/. Accessed 26 Mar 2024."},{"key":"2191_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95: e3863.","journal-title":"Medicine (Baltimore)"},{"key":"2191_CR18","first-page":"611","volume":"11","author":"A Ueda","year":"2015","unstructured":"Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management of Beh\u00e7et\u2019s disease. Ther Clin Risk Manag. 2015;11:611\u20139.","journal-title":"Ther Clin Risk Manag"},{"key":"2191_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55:679\u2013700.","journal-title":"J Gastroenterol"},{"key":"2191_CR20","unstructured":"JMDC Claims Database: JMDC. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 27 Nov 2023."},{"key":"2191_CR21","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2169\/internalmedicine.2035-18","volume":"58","author":"Y Kirino","year":"2019","unstructured":"Kirino Y, Nakajima H. Clinical and genetic aspects of Beh\u00e7et\u2019s disease in Japan. Intern Med. 2019;58:1199\u2013207.","journal-title":"Intern Med"},{"key":"2191_CR22","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/rheumatology\/kex285","volume":"56","author":"T Ishido","year":"2017","unstructured":"Ishido T, Horita N, Takeuchi M, et al. Clinical manifestations of Beh\u00e7et\u2019s disease depending on sex and age: results from Japanese nationwide registration. Rheumatology (Oxford). 2017;56:1918\u201327.","journal-title":"Rheumatology (Oxford)"},{"key":"2191_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ibd.21833","volume":"18","author":"YS Jung","year":"2012","unstructured":"Jung YS, Yoon JY, Hong SP, et al. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2012;18:1064\u201371.","journal-title":"Inflamm Bowel Dis"},{"key":"2191_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5152\/eurjrheum.2020.21199","volume":"8","author":"C G\u00fcrb\u00fcz","year":"2021","unstructured":"G\u00fcrb\u00fcz C, Yal\u00e7\u0131n Kehribar D, \u00d6zgen M. Clinical manifestations of Beh\u00e7et\u2019s syndrome: a single-center cohort of 777 patients. Eur J Rheumatol. 2021;8:211\u20136.","journal-title":"Eur J Rheumatol"},{"key":"2191_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","volume":"23","author":"J Zou","year":"2021","unstructured":"Zou J, Luo JF, Shen Y, et al. Cluster analysis of phenotypes of patients with Beh\u00e7et\u2019s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther. 2021;23:45.","journal-title":"Arthritis Res Ther"},{"key":"2191_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/bjd.12661","volume":"170","author":"DY Kim","year":"2014","unstructured":"Kim DY, Choi MJ, Cho S, et al. Changing clinical expression of Beh\u00e7et disease in Korea during three decades (1983\u20132012): Chronological analysis of 3674 hospital-based patients. Br J Dermatol. 2014;170:458\u201361.","journal-title":"Br J Dermatol"},{"key":"2191_CR27","first-page":"66","volume":"28","author":"Y Mizushima","year":"1988","unstructured":"Mizushima Y. Revised diagnostic criteria for Beh\u00e7et\u2019s disease in 1987. Ryumachi [Rheumatism]. 1988;28:66\u201370.","journal-title":"Ryumachi [Rheumatism]"},{"key":"2191_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5217\/ir.2016.14.2.111","volume":"14","author":"WK Ng","year":"2016","unstructured":"Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14:111\u20139.","journal-title":"Intest Res"},{"key":"2191_CR29","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s10067-023-06694-6","volume":"42","author":"P Mv","year":"2023","unstructured":"Mv P, Auanassova A, Yessirkepov M, et al. New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome. Clin Rheumatol. 2023;42:2761\u201375.","journal-title":"Clin Rheumatol"},{"key":"2191_CR30","doi-asserted-by":"publisher","first-page":"1337406","DOI":"10.3389\/fimmu.2024.1337406","volume":"15","author":"CO Hileman","year":"2024","unstructured":"Hileman CO, Malakooti SK, Patil N, et al. New-onset autoimmune disease after COVID-19. Front Immunol. 2024;15:1337406.","journal-title":"Front Immunol"},{"key":"2191_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1136\/annrheumdis-2021-220732","volume":"80","author":"M Barbhaiya","year":"2021","unstructured":"Barbhaiya M, Levine JM, Bykerk VP, et al. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis. 2021;80:1352\u20134.","journal-title":"Ann Rheum Dis"},{"key":"2191_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10067-021-05963-6","volume":"41","author":"M Barbhaiya","year":"2022","unstructured":"Barbhaiya M, Levine JM, Siegel CH, et al. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41:1619\u201322.","journal-title":"Clin Rheumatol"},{"key":"2191_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","volume":"24","author":"FR Spinelli","year":"2022","unstructured":"Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther. 2022;24:21.","journal-title":"Arthritis Res Ther"},{"key":"2191_CR34","doi-asserted-by":"publisher","first-page":"8176","DOI":"10.3390\/ijms24098176","volume":"24","author":"K He","year":"2023","unstructured":"He K, Yan X, Wu D. Intestinal Behcet\u2019s disease: a review of the immune mechanism and present and potential biological agents. Int J Mol Sci. 2023;24:8176.","journal-title":"Int J Mol Sci"},{"key":"2191_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5217\/ir.2017.15.3.318","volume":"15","author":"T Hisamatsu","year":"2017","unstructured":"Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Beh\u00e7et\u2019s disease. Intest Res. 2017;15:318\u201327.","journal-title":"Intest Res"},{"key":"2191_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/ecco-jcc\/jjaa172","volume":"15","author":"K Matsuoka","year":"2021","unstructured":"Matsuoka K, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021;15:358\u201366.","journal-title":"J Crohns Colitis"},{"key":"2191_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-019-1933-8","volume":"21","author":"I Miyagawa","year":"2019","unstructured":"Miyagawa I, Nakano K, Iwata S, et al. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet\u2019s disease. Arthritis Res Ther. 2019;21:151.","journal-title":"Arthritis Res Ther"},{"key":"2191_CR38","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00535-016-1300-3","volume":"52","author":"M Han","year":"2017","unstructured":"Han M, Jung YS, Kim WH, et al. Incidence and clinical outcomes of intestinal Beh\u00e7et\u2019s disease in Korea, 2011\u20132014: a nationwide population-based study. J Gastroenterol. 2017;52:920\u20138.","journal-title":"J Gastroenterol"},{"key":"2191_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jgh.13612","volume":"32","author":"JH Cheon","year":"2017","unstructured":"Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32:769\u201377.","journal-title":"J Gastroenterol Hepatol"},{"key":"2191_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5009\/gnl17462","volume":"12","author":"J Park","year":"2018","unstructured":"Park J, Cheon JH. Anti-tumor necrosis factor therapy in intestinal Beh\u00e7et\u2019s disease. Gut Liver. 2018;12:623\u201332.","journal-title":"Gut Liver"},{"key":"2191_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/jgh.15754","volume":"37","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liu J, Liu T, et al. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet\u2019s disease, a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:608\u201319.","journal-title":"J Gastroenterol Hepatol"},{"key":"2191_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3349\/ymj.2022.63.2.148","volume":"63","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Ma C, Dong R, et al. Efficacy and safety of anti-tumor necrosis factor-alpha agents for patients with intestinal Behcet\u2019s disease: a systematic review and meta-analysis. Yonsei Med J. 2022;63:148\u201357.","journal-title":"Yonsei Med J"},{"key":"2191_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11605-006-0031-9","volume":"11","author":"SJ Chou","year":"2007","unstructured":"Chou SJ, Chen VT, Jan HC, et al. Intestinal perforations in Beh\u00e7et\u2019s disease. J Gastrointest Surg. 2007;11:508\u201314.","journal-title":"J Gastrointest Surg"},{"key":"2191_CR44","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1007\/s10620-009-1095-7","volume":"55","author":"CM Moon","year":"2010","unstructured":"Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Beh\u00e7et\u2019s disease using clinical and colonoscopic findings. Dig Dis Sci. 2010;55:2904\u201311.","journal-title":"Dig Dis Sci"},{"key":"2191_CR45","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3349\/ymj.2013.54.5.1084","volume":"54","author":"JJ Park","year":"2013","unstructured":"Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Beh\u00e7et\u2019s disease. Yonsei Med J. 2013;54:1084\u201390.","journal-title":"Yonsei Med J"},{"key":"2191_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, et al. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med. 2021;22:118\u201327.","journal-title":"J Gen Fam Med"},{"key":"2191_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022;9:175\u201387.","journal-title":"Drugs Real World Outcomes"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02191-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:22:35Z","timestamp":1741087355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02191-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02191-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tadakazu Hisamatsu received grant support from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., Boston Scientific Corporation, Kissei Pharmaceutical Co. Ltd; consulting fees from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co., Ltd., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc. Kissei Pharmaceutical Co. Ltd. Makoto Naganuma received grants from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Kyorin Pharmaceutical Co., Ltd., Alfresa Pharma Corporation; and lecture fees from Tanabe Pharma Corporation, AbbVie GK, Takeda Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Gilead\u00a0Sciences, Inc. EA Pharma Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Philippe Pinton is employed by Ferring Pharmaceuticals, is a Board of Directors member at PharmaBiome and owns stocks of Takeda Pharmaceutical Co., Ltd. Mitsuhiro Takeno received consulting fees, speaking fees, and research grants from AbbVie GK, Amgen K. K., Asahi Kasei, Astellas Pharma Inc., Nippon Boehringer-Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K. K., Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku, Novartis, Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taisyo Pharma, UBC Japan, and Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}